Journals / Ulusal Cerrahi Dergisi / 2014 / Cilt: 30 - Sayı: 1

Completion thyroidectomy in differentiated thyroid cancer: When to perform?

Diferansiye tiroid kanserlerinde tamamlayıcı tiroidektomi: Ne zaman yapılmalı?

Pages
18–21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: Completion thyroidectomy is recommended in patients who have been diagnosed with differentiated thyroid cancer on histopathological evaluation, if their first operation was a conservative approach.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Completion thyroidectomy is recommended in patients who have been diagnosed with differentiated thyroid cancer on histopathological evaluation, if their first operation was a conservative approach.
📊
Key Findings & Data:The critical issue is when to do the second operation.Material and Methods: The medical records of 66 patients who underwent completion thyroidectomy for the treatment of differentiated thyroid cancer in our clinic between 2006-2013 were retrospectively analyzed.
💡
Conclusion & Impact:There was no statistically significant difference between the two groups in terms of complications after completion thyroidectomy.Conclusion: Although in some studies it is recommended that completion thyroidectomy should be performed either before scar tissue development or after clinical remission of scar tissue, edema and inflammation, we believe that timing of surgery has no effect on morbidity
🔬Design:Research Article
📍Scope:2006-2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Completion thyroidectomy is recommended in patients who have been diagnosed with differentiated thyroid cancer on histopathological evaluation, if their first operation was a conservative approach. The critical issue is when to do the second operation.Material and Methods: The medical records of 66 patients who underwent completion thyroidectomy for the treatment of differentiated thyroid cancer in our clinic between 2006-2013 were retrospectively analyzed. All data were compared after patients were divided into two groups according to the interval between the first surgery and completion thyroidectomy.Results: Fifty-two patients (78.8%) were women and 14 patients (21.2%) were male. Completion thyroidectomy was performed 10-90 days after the initial surgery (group 1) in 26 patients, whereas it was performed later than 90 days in 40 patients (group 2). Temporary hypoparathyroidism occurred in two patients (7.7%) in group 1, and in 3 patients (7.5%) in group 2. Transient recurrent laryngeal nerve palsy was observed in 1 patient (3.9%) in group 1, and in 1 patient (2.5%) in group 2. There were no permanent morbidities in both groups. Residual tumor rate after completion thyroidectomy was 45.5%. There was no statistically significant difference between the two groups in terms of complications after completion thyroidectomy.Conclusion: Although in some studies it is recommended that completion thyroidectomy should be performed either before scar tissue development or after clinical remission of scar tissue, edema and inflammation, we believe that timing of surgery has no effect on morbidity

Özet

Amaç: İlk ameliyatta konservatif yaklaşım tercih edilen, histopatolojik değerlendirme sonucunda diferansiye tiroid kanseri saptanan hastalarda tamamlayıcı tiroidektomi sıklıkla savunulan bir yaklaşımdır. Kritik nokta ikinci operasyonun ne zaman yapılacağıdır.Gereç ve Yöntemler: Kliniğimizde 2006-2013 tarihleri arasında diferansiye tiroid kanserinin tedavisi için tamamlayıcı tiroidektomi uygulanan 66 hastanın kayıtları retrospektif olarak incelendi. İlk ameliyat ile tamamlayıcı tiroidektomi arasındaki süreye göre hastalar iki gruba ayrılarak tüm veriler karşılaştırıldı.Bulgular: Hastaların 52'si (%78,8) kadın, 14'ü (%21,2) erkek idi. Yirmi altı hastada tamamlayıcı tiroidektomi ilk ameliyattan sonraki 10-90 gün içinde (grup 1), 40 hastada ise 90 gün veya daha sonra (grup 2) uygulanmıştı. Geçici hipoparatiroidizm grup 1'de 2 hastada (%7,7), grup 2'de 3 hastada (%7,5) ve geçici rekürren laringeal sinir paralizisi grup 1'de 1 hastada (%3,9), grup 2'de de 1 hastada (%2,5) meydana geldi. Her iki grupta da kalıcı morbidite gelişmedi. Tamamlayıcı tiroidektomi sonrası rezidü tümör oranı %45,5 idi. Gruplar arasında tamamlayıcı tiroidektomi sonrası komplikasyonlar açısından yapılan karşılaştırmada istatistiksel olarak anlamlı fark bulunmadı. Sonuç: Bazı çalışmalarda tamamlayıcı tiroidektominin skar dokusu gelişmeden ya da skar, ödem ve inflamasyonun yatışması sonrası yapılması önerilmesine karşılık biz tamamlayıcı tiroidektomi zamanının morbidite üzerinde etkisi olmadığı kanaatindeyiz

🔖

Cite This Article

KISAOĞLU, A., ÖZOĞUL, B., AKÇAY, M. N., ÖZTÜRK, G., ATAMANALP, S. S., AYDINLI, B., KARA, S. (2014). Completion thyroidectomy in differentiated thyroid cancer: When to perform?. Ulusal Cerrahi Dergisi, Cilt: 30 - Sayı: 1, 18–21. https://ajindex.com/articles/325424

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Mittendorf EA, McHenry CR. Thyroidectomy for selected patients with thyrotoxicosis. Arch Otolaryngol Head Neck Surg 2001; 127: 61-65. [CrossRef] 2. Mishra A, Agarwal A, Agarwal G, Mishra SK. Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg 2001; 25: 307-310. [CrossRef] 3. Udelsman R, Shaha AR. Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer? Lancet Oncol 2005; 6: 529-531. [CrossRef] 4. Gimm O. Thyroid cancer. Cancer Lett 2001; 163: 143-156. [CrossRef] 5. Shaha AR. Thyroid cancer: extent of thyroidectomy. Cancer Control 2000; 7: 240-245. 6. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9: 421-427. [CrossRef] 7. Akcan A, Sözüer E, Akyıldız H, Akgün H, Küçük C, Ok E, et al. İyi diferansiye tiroid kanserlerinde tamamlayıcı tiroidektomi-Retrospektif klinik araştırma. Ulusal Cer Derg 2008; 24: 83-88. 8. Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidencebased review. World J Surg 2008; 32: 1313-1324.[CrossRef] 9. Clark OH, Levin K, Zeng QH, Greenspan FS, Siperstein A. Thyroid cancer: the case for total thyroidectomy. Eur J Cancer Clin Oncol 1988; 24: 305-313. [CrossRef] 10. Dralle H. Maligne Schilddruesentumoren. In: Krebsgesellschaft D (ed). Kurzgefasste interdisziplinäre leitlinien 2008.
  2. Zuckerschwerdt Verlag, Munich, Germany. 2008. 11. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214. [CrossRef] 12. Auguste LJ, Attie JN. Completion thyroidectomy for initially misdiagnosed thyroid cancer. Otolaryngol Clin North Am 1990; 23: 429-439. 13. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003; 98: 31-40. [CrossRef] 14. Rosário PW, Fagundes TA, Borges MA, Padrão EL, Rezende LL, Barroso AL, et al. Completion thyroidectomy in patients with thyroid carcinoma initially submitted to lobectomy. Clin Endocrinol 2004; 61: 652-653. [CrossRef] 15. Delbridge L, Parkyn R, Philips J, Barraclough B, Robinson B. Minimally invasive follicular thyroid carcinoma: completion thyroidectomy or not? ANZ J Surg 2002; 72: 844-845. [CrossRef] 16. Davies L, Welch HG. Surgery of thyroid c